The exact mechanism of HIV infection of CD4+ T cellsAnyone provide any papers on how HH1 and HR2 of gp41 act when the virus gain entry into the cells?Can just give me the title of the articles. thanks.

The exact mechanism of HIV infection of CD4+ T cellsAnyone provide any papers on how HH1 and HR2 of gp41 act when the virus gain entry into the cells?Can just give me the title of the articles. thanks.
The exact mechanism of HIV infection of CD4+ T cells
Anyone provide any papers on how HH1 and HR2 of gp41 act when the virus gain entry into the cells?
Can just give me the title of the articles. thanks.

The exact mechanism of HIV infection of CD4+ T cellsAnyone provide any papers on how HH1 and HR2 of gp41 act when the virus gain entry into the cells?Can just give me the title of the articles. thanks.
[1]Cooley LA, Lewin SR . HIV-1 cell entry and advances in viral entry inhibitor therapy[J] . J Clin Virol , 2003, (26): 121.
[2]Goto T, Nakai M, Ikuta K. The life-cycle of human immunodeficiecy virus type 1[J]. Micron,1998,29(2/3):123.
[3]王颖,王晓峰,傅学奇.HIV-1复制抑制剂的新靶标[J].生命的化学,2001,21(6):485.
[4]魏文青,王明霞.抗病毒药物的分子靶标[J].国外医学·药学分册,2001,28(5):266.
[5]Jacobson JM, Lowy I, Fletcher CV, et al. Single-dose safety,phacmacology, and antiviral activity of the human immunodeficiecy virus (HIV) type 1 entry inhibitor PRO542 in HIV-infected adults[J]. J Infect Dis ,2000,182(1) :326.
[6]Shearer WT, Israel RT, Starr S, et al. Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2study[J]. J Infect Dis ,2000,182(6): 1774.
[7]Esser M, Mori T, Mondor I, et al. Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding,fusion,and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120[J]. J Virol ,1999 , 73 : 4360 .
[8]Wyatt R, Kwong P, Desjardins E, et al. The antigenic structure of the HIV gp120 envelope glucoprotein[J]. Nature, 1998,393:705.
[9]徐志凯,姜世勃.针对HIV-1进入细胞过程的抑制剂研究进展[J].细胞与分子免疫学杂志,2001,17(5):401.
[10]Hoshino H. Coreceptors of H1V infection and the development of HIV entry inhibitors: overview and targets[J]. Jpn J Clin Med, 2002,60(1):81.
[11]Berson J F, Doms R W. Structure-function studies of the HIV-1 coreceptors[J]. Semin Immunol , 1998,10:237.
[12]Bleul C, Farzan M, Choe H, et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTER/fusin and blocks HIV-1 entry[J]. Nature, 1996,382: 829.
[13]Deng H, Liu RH, Ellmeier W, et al. Identification of a majorco-receptor for primary isolates of HIV-1[J]. Nature, 1996,381:661.
[14]张应玖,金宁一,殷震,等.HIV的致病机制研究进展[J].微生物学杂志,2000,20(1):42.
[15]Zaitseva M, Peden K, Golding H. HIV coreceptors:role of structure, posttranslational modifications, and intemalization in viral-cell fusion and as targets for entry inhibitors [J]. Biochim Biophys Acta, 2003,1614:51.
[16]Speck RF, Wehrly K, Platt EJ, et al. Selective employment of chemokine receptors as human immunodeficiecy virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop [J]. J Viral, 1997,71:7136.
[17]Sabbe R, Picchio GR, Pastore C, et al. Donor- and ligand-dependent differences in C-C chemokine receptor 5 reexpression[J]. J Virol,2001,75(2) :661.
[18]Tamamura H, Omagari A, Oishi S. Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective antiHIV agents with very high selectivity indexes[J]. Bioorg Med Chem Lett ,2000,10(23) :2633.
[19]Dirk D, Dominique S, Myriam W, et al. A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: inhibitor of human immunodeficiecy virus replication by blocking CXCR4-mediated virus entry[J]. Mol Pharmacol, 2000, 57(1): 116.
[20]董肖椿,闻韧.作用于趋化因子受体的新型抗HIV药物研究进展[J].药学学报,2001,36(10):796.
[21]de Clercq E. New developments in anti-HIV chemotherapy[J]. Biochim Biophys Acta ,2002,1587:258.
[22]EsteJ, CabreraC, BlancoJ, etal. Shift of clinical human immunodeficiecy virus type 1 isolates from X4 to R5 and prevention of the formarion of syncytium-inducing phenotype by blockade of CXCR4[J]. J Virol , 1999,73: 5577.
[23]O'Hara BM, Olson WC. HIV entry inhibitors in clinical development [J]. Curr Opin Pharmcol, 2002, 2(5):523.
[24]Lynch CL, Hale JJ, Budhu RJ, et al. 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 4: Synthesis of N-1 acidic functionality affording analogues with enhanced antiviral activity against HIV[J]. Bioorg Med Chem Lett , 2002,12:3001.
[25]Labranche CC, Galasso G, Moore JP, et al. HIV fusion and its inhibition[J]. Antiviral Res,2001,50: 95.
[26]O'Brien SJ,Moore JP. The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS[J].Immunol Rev ,2000,177:99.
[27]Jiang S, Zhao Q, Debnath AK. Peptide and non-peptide HIV fusion inhibitors [J]. Curr Pharm Des, 2002,8 (8): 563.
[28]邱阳.HIV-1进攻靶细胞的机制及相应环节抑制剂的研究进展[J].生物物理学报,2002,18(1):11.
[29]Biscone MJ, Pierson TC, Doms RW. Opportunities and challenges in targeting HIV entry[J]. Curr Opin Pharmcol,2002,2 (5):529.
[30]Fletcher CV. Enfuvirtide, a new drug for HIV infection [J]. Lancet,2003,361:1577.
[31]Starr-Spires LD, Collman RG. HIV-1 entry and entry inhibitors as therapeutic agents [J]. Clin Lab Med, 2002,22(3): 681.
[32]Chan DC, Chutkowski CT, Kim PS. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target[J].Proc Natl Acad Sci USA, 1998,95:15613.
[33]Root MJ, Kay MS, Kim PS. Protein design of an HIV-1 entry inhibitor[J]. Science ,2001,291:884.
[34]Jiang S, Debnath AK. Development of HIV entry inhibitors targeted to the coiled-coil regions of gp41 [J]. Biochem Biophys Res Commun ,2000,269:641.
[35]姜世勃,张力.人类免疫缺陷病毒包膜糖蛋白gp41核心结构的药物研究[J].国外医学·微生物学分册,2000,23(4):31.
[36]Xavier S, Gerhard H. Hydrophobicity maps of the N-peptide coiled coil of HIV-1 gp41[J] . Biochemistry,2002,41(9) :2956.
[37]王峥涛.治疗HIV感染的先导天然化合物[J].国外医学·药学分册,2001,28(4):227.

HIV-1进攻靶细胞的机制及相应环节抑制剂的研究进展
ADVANCES IN MECHANISMS OF HIV- 1 ATTACKING HOST CELLS AND INHIBITORS IN RELATED STEPS
the most helpful website(many articles)
http://www.ilib.cn/A-swwlxb200201002.html